[Ambulatory long-term management of a left ventricular assist device. Current modality in terminal heart failure].

M T R Grapow, A Todorov, F Bernet, H R Zerkowski
{"title":"[Ambulatory long-term management of a left ventricular assist device. Current modality in terminal heart failure].","authors":"M T R Grapow,&nbsp;A Todorov,&nbsp;F Bernet,&nbsp;H R Zerkowski","doi":"10.1024/1023-9332.9.1.27","DOIUrl":null,"url":null,"abstract":"<p><p>We report about the first use and successful outpatient therapy with an implantable pulsatile left ventricular assist device (LVAD, Novacor) in a patient with a combined dilative and ischemic cardiomyopathy in Switzerland. The patient, a 51 year old man (112 kg, 191 cm, blood type A) developed end-stage heart failure (New York Heart Association class (NYHA) IV) while he was awaiting orthotopic heart transplantation. Due to his profession as an independent graphic-designer the patient was afraid of a long-term temporary disablement with consecutive bankruptcy. Therefore we decided and performed the implantation of a Novacor-LVAD as a bridge to transplantation with the possibility to outpatient therapy in a favourable course. The patient was supported by the device for more than five months. His cardiac functional status returned to NYHA class I, and the patient was discharged 5 weeks after implantation. He returned into his normal life and started working at 100% again. Furthermore the LVAD enabled the patient to participate in almost all activities. Five months (151 days) after implantation a donor organ became available and the patient underwent orthotopic heart transplantation. The use and successful outpatient therapy with an implantable pulsatile left ventricular assist device in our patient has proved to be save, reliable, life-saving, quality of life improving and could be an important alternative for the economic burden in heart failure therapy.</p>","PeriodicalId":79425,"journal":{"name":"Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera","volume":"9 1","pages":"27-30"},"PeriodicalIF":0.0000,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1024/1023-9332.9.1.27","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

We report about the first use and successful outpatient therapy with an implantable pulsatile left ventricular assist device (LVAD, Novacor) in a patient with a combined dilative and ischemic cardiomyopathy in Switzerland. The patient, a 51 year old man (112 kg, 191 cm, blood type A) developed end-stage heart failure (New York Heart Association class (NYHA) IV) while he was awaiting orthotopic heart transplantation. Due to his profession as an independent graphic-designer the patient was afraid of a long-term temporary disablement with consecutive bankruptcy. Therefore we decided and performed the implantation of a Novacor-LVAD as a bridge to transplantation with the possibility to outpatient therapy in a favourable course. The patient was supported by the device for more than five months. His cardiac functional status returned to NYHA class I, and the patient was discharged 5 weeks after implantation. He returned into his normal life and started working at 100% again. Furthermore the LVAD enabled the patient to participate in almost all activities. Five months (151 days) after implantation a donor organ became available and the patient underwent orthotopic heart transplantation. The use and successful outpatient therapy with an implantable pulsatile left ventricular assist device in our patient has proved to be save, reliable, life-saving, quality of life improving and could be an important alternative for the economic burden in heart failure therapy.

左心室辅助装置的长期动态管理。终末期心力衰竭的当前模式[j]。
我们报道了瑞士首例可植入搏动左心室辅助装置(LVAD, Novacor)在合并扩张性和缺血性心肌病患者中的首次使用和成功的门诊治疗。患者,51岁男性(112公斤,191厘米,a型血),在等待原位心脏移植时出现终末期心力衰竭(纽约心脏协会(NYHA) IV级)。由于他的职业是一个独立的平面设计师,病人害怕长期暂时残疾,连续破产。因此,我们决定植入Novacor-LVAD作为移植的桥梁,并有可能在一个有利的过程中进行门诊治疗。该患者依靠该装置支撑了5个多月。患者心功能恢复到NYHA I级,植入5周后出院。他恢复了正常的生活,又开始了100%的工作。此外,LVAD使患者能够参加几乎所有的活动。植入后5个月(151天)供体器官可用,患者接受原位心脏移植。在本例患者的门诊治疗中,植入搏动左心室辅助装置的使用和成功已被证明是节省,可靠,挽救生命,改善生活质量,并可能成为心力衰竭治疗经济负担的重要替代方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信